Agenebio
CompanyUnited StatesFounded 2008
Agenebio develops one asset, in phase 2 (AGB101 in Parkinson disease psychosis). Mostly small molecule acting on SV2A; based in the United States, founded in 2008.
- 1
- Asset
- Furthest stage
- Phase 2
- 9
- Grants
- 1
- Trial
- 2
- Signals
Pipeline
1Low-dose extended-release levetiracetam targeting SV2A to modulate neural hyperactivity.
Phase 2, Small molecule, SV2A, Parkinson disease psychosis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials3
- People3
- Signals2
- Similar companies2